Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For patients who have never been treated for lymphoma (Cohort 1):

• You have been diagnosed with a specific type of lymphoma called DLBCL, confirmed by a tissue test, and have not yet received any treatment for it.
• Your lymphoma is at stage II, III, or IV.
• Your doctors expect you to live for at least 12 months.

For patients whose lymphoma has come back or stopped responding to treatment (Cohorts 2 & 3):

• You have been diagnosed with DLBCL (confirmed by a tissue test) and have already completed a standard first-line treatment that included a CD20-targeting antibody drug and a type of chemotherapy (such as R-CHOP).
• Your lymphoma either came back after treatment or did not respond to it.
• If you have only had one round of treatment and have not had a stem cell transplant, your doctor has decided that intensive chemotherapy and a stem cell transplant are not suitable for you, or you have chosen not to have them.
• Your doctors expect you to live for at least 6 months.

All participants must also meet these criteria:

• You are 18 years of age or older.
• You are well enough to carry out most daily activities (a general health score of 0–2 on a standard medical scale).
• At least one area of lymphoma can be clearly seen and measured on a CT or MRI scan, and it shows up on a PET/CT scan.
• Your blood counts and organ function (such as kidneys and liver) are at acceptable levels.
• You do not have any serious uncontrolled health conditions.
• You are able to attend all required appointments and follow the study schedule.
• You are willing to follow the birth control requirements set out by the trial.
• You are willing to sign a consent form before any study procedures begin.

Who may not be able to join:

For previously treated patients (Cohorts 2 & 3):

• You have had a stem cell transplant, cell therapy, or gene therapy within the last 90 days, received radiation therapy within the last 14 days, or have not waited long enough after your last chemotherapy, targeted therapy, or antibody treatment before starting this trial (confirm with trial site for specific timing).

All patients will likely not be able to join if:

• Your DLBCL developed from a slower-growing lymphoma, is a type called primary mediastinal lymphoma, involves the brain or spinal cord, or has specific genetic changes involving MYC and BCL2.
• You have previously taken a type of drug called a BTK inhibitor.
• You have received a live or viral vector vaccine (such as some types of flu or other vaccines) within the past 4 weeks.
• You are currently taking blood thinners called vitamin K antagonists, two or more blood-thinning or anti-clotting medicines at the same time, certain drugs or supplements that strongly affect a liver enzyme called CYP3A, stomach acid-reducing drugs called proton pump inhibitors, or certain herbal anti-cancer treatments — or you have not stopped these medications long enough before the trial (confirm with trial site).
• You have had major surgery within the last 4 weeks, are expected to need surgery during the trial, or have not fully recovered from a previous procedure or treatment.
• You have significant heart problems, or have had a blood clot, stroke, or bleeding in the brain within the past 6 months.
• You have an active infection.
• You have ongoing nausea, vomiting, a long-term digestive condition, difficulty swallowing, or have had part of your intestine removed, which could affect how well your body absorbs the trial medication.
• You have been diagnosed with another type of cancer (other than B-cell lymphoma) within the past 2 years.
• You are known to be allergic to any ingredients in the trial drug (DZD8586) or to similar types of drugs.
• You have severely uncontrolled high blood pressure or a condition that causes unusual bleeding.
• You have a serious physical or mental health condition that could affect your ability to take part in or give informed consent for the study.
• You are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.